Immatics N.V. (IMTX)

NASDAQ: IMTX · Real-Time Price · USD
4.255
-0.085 (-1.96%)
At close: May 9, 2025, 4:00 PM
4.240
-0.015 (-0.35%)
After-hours: May 9, 2025, 4:41 PM EDT
-1.96%
Market Cap 515.37M
Revenue (ttm) 161.34M
Net Income (ttm) 15.76M
Shares Out 121.55M
EPS (ttm) 0.14
PE Ratio 29.25
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 555,727
Open 4.430
Previous Close 4.340
Day's Range 4.225 - 4.460
52-Week Range 3.300 - 13.770
Beta 0.87
Analysts Strong Buy
Price Target 16.67 (+291.77%)
Earnings Date May 20, 2025

About IMTX

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Harpreet Singh
Employees 682
Stock Exchange NASDAQ
Ticker Symbol IMTX
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for IMTX stock is "Strong Buy." The 12-month stock price forecast is $16.67, which is an increase of 291.77% from the latest price.

Price Target
$16.67
(291.77% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of...

17 days ago - GlobeNewsWire

Immatics N.V.: Trading Below Cash, But Not Without Reason

Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but neg...

6 weeks ago - Seeking Alpha

Immatics Announces Full Year 2024 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of...

6 weeks ago - GlobeNewsWire

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics

6 months ago - GlobeNewsWire

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers

6 months ago - GlobeNewsWire

Immatics: A Promising TCR Pipeline

Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation...

7 months ago - Seeking Alpha

Immatics Announces Pricing of $150 Million Public Offering

H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redire...

7 months ago - GlobeNewsWire

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

On Thursday, Immatics N.V.  IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million.

7 months ago - Benzinga

Immatics Announces Proposed $150 Million Public Offering

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...

7 months ago - GlobeNewsWire

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST

7 months ago - GlobeNewsWire

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development o...

7 months ago - GlobeNewsWire

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Houston, Texas and Tuebingen, Germany, September 16, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and developmen...

8 months ago - GlobeNewsWire

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and developmen...

8 months ago - GlobeNewsWire

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, August 13, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development o...

9 months ago - GlobeNewsWire

Immatics Announces First Quarter 2024 Financial Results and Business Update

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME

1 year ago - GlobeNewsWire

Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case

Immatics, a German biotech company, achieved its Nasdaq listing in 2020 through a merger with Arya Sciences Acquisition Corp, a SPAC sponsored by Perceptive Advisors. The company focuses on developing...

1 year ago - Seeking Alpha

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Houston, Texas and Tuebingen, Germany, March 21, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...

1 year ago - GlobeNewsWire

Immatics: Pioneering TCR Therapies In The Fight Against Cancer

Immatics is a significant player in T-cell redirecting cancer immunotherapies, with a clinical-stage pipeline showing promising interim results. The company has formed strategic partnerships with Mode...

1 year ago - Seeking Alpha

Immatics Announces Pricing of $175 Million Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...

1 year ago - GlobeNewsWire

Immatics Announces Proposed Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...

1 year ago - GlobeNewsWire

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Tuebingen, Germany and Houston, TX, November 14, 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...

1 year ago - GlobeNewsWire

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET

1 year ago - GlobeNewsWire

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types Regulatory activities und...

1 year ago - GlobeNewsWire

Analyzing Immatics' Multi-Faceted Investment Case

Immatics showcases a robust financial position and promising IMA203 TCR-T cell therapy for oncology with impressive safety and efficacy data. Risks include high competition in T-cell therapies, potent...

1 year ago - Seeking Alpha

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

Appointment effective as of September  14, 2023; Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel , Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX),...

Other symbols: PLX
1 year ago - PRNewsWire